Detrusin LA Capsule (Extended Release) 2 mg

Detrusin LA Capsule (Extended Release) 2 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Detrusin LA Capsule (Extended Release) 2 mg
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Detrusin LA Capsule (Extended Release) 2 mg
Generic	Tolterodine Tartrate
Weight	2 mg
Type	Capsule (Extended Release)
Therapeutic Class	BPH/ Urinary retention/ Urinary incontinence
Manufacturer	UniMed UniHealth Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Detrusin LA Capsule (Extended Release) 2 mg is indicated for the treatment of an overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Dosage

Detrusin LA Capsule (Extended Release) 2 mg dosage

Extended-release capsule: The recommended dose is Detrusin LA Capsule (Extended Release) 2 mg 4 mg once daily. The dose may be lowered to 2 mg once daily based on individual response and tolerability. For patients with significantly reduced hepatic or renal function or who are currently taking drugs that are potent inhibitors of CYP3A4, the recommended dose is Detrusin LA Capsule (Extended Release) 2 mg 2 mg daily.Film-coated tablet: The recommended dose is Detrusin LA Capsule (Extended Release) 2 mg 2 mg twice daily except in patients with impaired liver function or severely impaired renal function (GFR<30 ml/min) for whom the recommended dose is one Detrusin LA Capsule (Extended Release) 2 mg 1 mg tablet twice daily. In case of troublesome side effects, the dose may be reduced from 2 mg to 1 mg twice daily. The effect of treatment should be re-evaluated after 2-3 months.Pediatric use: The safety and effectiveness of tolterodine in children have not been established.Geriatric use: No overall differences in safety were observed between the older and youngerpatients treated with Tolterodine.

Side Effects

The most common side effects reported by patients receiving Detrusin LA Capsule (Extended Release) 2 mg were dry mouth, headache, constipation, and abdominal pain. Dry mouth was the most frequently reported adverse event for patients treated with Detrusin LA Capsule (Extended Release) 2 mg tablets occurring in 23.4% of patients treated with Detrusin LA Capsule (Extended Release) 2 mg tablets and 7.7% of placebo-treated patients. Dry mouth, constipation, abnormal vision (accommodation abnormalities), urinary retention, and dry eyes are expected side effects of antimuscarinic agents. The adverse events were reported regardless of causality.

Precaution

Detrusin LA Capsule (Extended Release) 2 mg should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention and to patients with gastrointestinal obstructive disorders, such as pyloric stenosis, because of the risk of gastric retention and in patients being treated for narrow-angle glaucoma. For patients with significantly reduced hepatic function or renal function, the recommended dose for Detrusin LA Capsule (Extended Release) 2 mg is 2 mg daily. In a study of the effect of Detrusin LA Capsule (Extended Release) 2 mg immediate release tablets on the QT interval, the effect on the QT interval appeared greater for 8 mg/day (two times the therapeutic dose) compared to 4 mg/day and was more pronounced in CYP2D6 poor metabolizers than extensive metabolizers. The effect of Tolterodine 8 mg/day was not as large as that observed after four days of therapeutic dosing with the active control moxifloxacin. However, the confidence intervals overlapped. These observations should be considered in clinical decisions to prescribe Detrusin LA Capsule (Extended Release) 2 mg tablets for patients with a known history of QT prolongation or patients who are taking Class I A (e.g., quinidine, procainamide) or Class III (e.g.,amiodarone, sotalol) antiarrhythmic medications. Patients should be informed that antimuscarinic agents such as Detrusin LA Capsule (Extended Release) 2 mg tablets may produce the following effects: blurred vision, dizziness, or drowsiness.

Interaction

Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of Tolterodine when co-administered to subjects who were poor metabolizers. For patients receiving Ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, Itraconazole, Miconazole) or Macrolide antibiotics (eg, Erythromycin, Clarithromycin) or Cyclosporine or Vinblastine, the recommended dose of Detrusin LA Capsule (Extended Release) 2 mg is 2 mg daily.

Pregnancy & Breastfeeding use

There are no studies of Tolterodine in pregnant women. Therefore, Detrusin LA Capsule (Extended Release) 2 mg tablets should be used during pregnancy only if the potential benefit for the mother justifies the potential risk to the fetus. It is not known whether Tolterodine is excreted in human milk. Therefore, Detrusin LA Capsule (Extended Release) 2 mg tablets should not be administered during nursing. A decision should be made whether to discontinue nursing or to discontinue Detrusin LA Capsule (Extended Release) 2 mg tablets in nursing mothers.

Contraindication

Detrusin LA Capsule (Extended Release) 2 mg is contra-indicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, or in patients who have demonstrated hypersensitivity to Detrusin LA Capsule (Extended Release) 2 mg.

Acute Overdose

Overdosage with Detrusin LA Capsule (Extended Release) 2 mg capsules can potentially result in severe central anticholinergic effects and should be treated accordingly. ECG monitoring is recommended in the event of overdosage.